Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747966 | 0.91 | NAMPT (0.40) | MAPTTP53THRBNAMPTKEAP1 | |
| SCHEMBL3597771 | 0.91 | PKM (0.40) | MAPTTP53THRBNAMPTKEAP1 | |
| SCHEMBL4304911 | 0.91 | NAMPT (0.38) | MAPTTP53THRBNAMPTKEAP1 | |
| SCHEMBL3205594 | 0.78 | CHRM2 (0.41) | MAPTTP53THRBKEAP1NFE2L2 | |
| SCHEMBL5747972 | 0.77 | JAK2 (0.35) | — | |
| SCHEMBL5747052 | 0.76 | KCNH2 (0.36) | GPR119 | |
| SCHEMBL10313867 | 0.76 | USP30 (0.48) | — | |
| SCHEMBL5746081 | 0.75 | MAPT (0.42) | MAPTTP53THRBKEAP1NFE2L2 | |
| SCHEMBL4149910 | 0.75 | IDO1 (0.47) | MAPTTP53THRBKEAP1NFE2L2 | |
| SCHEMBL12066909 | 0.75 | GPR183 (0.41) | MAPTTP53THRBNAMPTKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | MAPT 3830/4885TP53 1940/4885THRB 3438/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | MAPT 4448/4885TP53 2210/4885THRB 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.